BMS buys Mi­rati for $4.8B; Pfiz­er to slash cost; Q&A with Ver­tex CSO; Al­ny­lam's On­pat­tro set­back; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Af­ter Mi­rati opened the week with a multi­bil­lion-dol­lar buy­out, we take a look at Bris­tol My­ers Squibb’s bud­ding ri­val­ry with Am­gen, Pfiz­er’s planned cost cuts, a sur­prise CRL for Al­ny­lam, a busy stream of clin­i­cal read­outs and much, much more. Don’t miss our roundup of the key take­aways from our #Eu­ro­Bio23 sum­mit in Lon­don.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER